Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

Patients taking Pfizer’s Lorlatinib (after developing resistance to Crizotinib) can develop the L1198F mutation. The L1198F mutation causes the cancer cells that were previously resistant to Crizotinib to become sensitive to Crizotinib again.

Essentially the two drugs can require mutually incompatible mutations in cancer cells to develop resistance. This is similar to what the AIDS “cocktail” of drugs did to the AIDS virus. However, if the L1198F mutation developed in the central nervous system then Crizotinib probably would not be able to reach it with much effectiveness.

http://www.ncbi.nlm.nih.gov/pubmed/26698910

This entry was posted in 3922 - lorlatinib by Pfizer, Brain metastases, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment. Bookmark the permalink.

Leave a Reply